Karyopharm TherapeuticsKPTI
13F holders, Q3 2025 (September 30)1holders
0new positions
0sold out
$6.54avg. 13F price*
At the end of Q3 2025, 1 institutions reported holding Karyopharm Therapeutics Inc. (KPTI) in their 13F filings, unchanged from Q2 2025. 0 opened new positions and 0 sold out. The largest holder was Birchview Capital, LP ($183K).
- Company
- Karyopharm Therapeutics Inc.
- CUSIP
- 48576U106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 1 holders
| Birchview Capital, LP | 0.14% | No change | 27,985 | $183K |
"% of holder's portfolio" is KPTI's weight in each manager's 13F, not the share of Karyopharm Therapeutics Inc. the manager owns.